A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

Xing Zhang,Xizhi Wen,Chen Yang,Shan Zeng,Lichuang Men,Hengbang Wang,Yuxiang Ma,Yang Zhang,Ruiqing Peng,Desheng Weng,Li Zhang,Jiao Ji,Wenqin Liu,Zhiyan Liang,Yingjie Huang,Dajun Yang,Yifan Zhai

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

2019

Xing Zhang
Xizhi Wen
Chen Yang
Shan Zeng
Lichuang Men
Hengbang Wang
Yuxiang Ma
Yang Zhang
Ruiqing Peng
Desheng Weng
Li Zhang
Jiao Ji
Wenqin Liu
Zhiyan Liang
Yingjie Huang
Dajun Yang
Yifan Zhai

3124Background: APG-115 is a novel and orally active small-molecule MDM2 inhibitor. APG-115 alone or in combination with chemotherapeutic, targeted or IO agents have shown potent antitumor activiti...

Keywords:

Antagonist
Soft tissue
Pathology
Medicine
Mdm2
Pharmacology
mdm2 p53
phase i study
orally active

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations